Holen Sie sich die Stockscreener-App
44.19
2.18%
-0.845
Handel nachbörslich:
44.21
0.025
+0.06%
Schlusskurs vom Vortag:
$45.03
Offen:
$45.35
24-Stunden-Volumen:
772.17K
Relative Volume:
0.79
Marktkapitalisierung:
$3.53B
Einnahmen:
$541.74M
Nettoeinkommen (Verlust:
$88.01M
KGV:
40.68
EPS:
1.0862
Netto-Cashflow:
$155.34M
1W Leistung:
+5.66%
1M Leistung:
+28.31%
6M Leistung:
-7.67%
1J Leistung:
+62.19%
1-Tages-Spanne:
$43.95
$45.52
1-Wochen-Bereich:
$41.86
$46.00
52-Wochen-Spanne:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
44.23 | 3.59B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo - TradingView
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally? - TradingView
Here's Why Veracyte (VCYT) is a Strong Momentum Stock - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - Yahoo Finance UK
Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests - Yahoo Finance
Veracyte director Robert S Epstein sells $440,129 in company stock - Investing.com India
Insider Sell: Robert Epstein Sells 10,000 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte director Robert S Epstein sells $440,129 in company stock By Investing.com - Investing.com Australia
Veracyte Insider Sold Shares Worth $440,129, According to a Recent SEC Filing - Moomoo
Veracyte (VCYT) director sells 10,000-share block under 10b5-1 plan - Stock Titan
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
Kevin Haas Named Chief Development and Technology Officer at Veracyte - Medical Product Outsourcing
Veracyte Jumps 7.8% Amid Sector-Wide Rally - AlphaStreet
[144] VERACYTE, INC. SEC Filing - Stock Titan
Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test - Sahm
Veracyte to Participate in Upcoming June 2026 Investor Conferences - BioSpace
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte stock (US92347M1009): diagnostics specialist back in the spotlight after new data and index - AD HOC NEWS
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Maintains Target Price $42 - Moomoo
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term - Yahoo Finance
A Look At Veracyte (VCYT) Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test - Sahm
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage By Investing.com - Investing.com South Africa
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):